197 related articles for article (PubMed ID: 16888271)
1. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation.
Lip GY; Lane D; Van Walraven C; Hart RG
Stroke; 2006 Sep; 37(9):2294-300. PubMed ID: 16888271
[TBL] [Abstract][Full Text] [Related]
2. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients.
Roldán V; Marín F; Muiña B; Torregrosa JM; Hernández-Romero D; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2011 Jun; 57(25):2496-504. PubMed ID: 21497043
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation.
Krishnamoorthy S; Khoo CW; Lim HS; Lane DA; Pignatelli P; Basili S; Violi F; Lip GY
Eur J Clin Invest; 2013 Oct; 43(10):1032-8. PubMed ID: 23961715
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation.
Conway DS; Pearce LA; Chin BS; Hart RG; Lip GY
Circulation; 2003 Jul; 107(25):3141-5. PubMed ID: 12796127
[TBL] [Abstract][Full Text] [Related]
5. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation.
Roldán V; Marín F; García-Herola A; Lip GY
Thromb Res; 2005; 116(4):321-5. PubMed ID: 16038717
[TBL] [Abstract][Full Text] [Related]
6. Progressive endothelial damage revealed by multilevel von Willebrand factor plasma concentrations in atrial fibrillation patients.
Scridon A; Girerd N; Rugeri L; Nonin-Babary E; Chevalier P
Europace; 2013 Nov; 15(11):1562-6. PubMed ID: 23689486
[TBL] [Abstract][Full Text] [Related]
7. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
Lip GY; Nieuwlaat R; Pisters R; Lane DA; Crijns HJ
Chest; 2010 Feb; 137(2):263-72. PubMed ID: 19762550
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation.
Freynhofer MK; Gruber SC; Bruno V; Höchtl T; Farhan S; Zaller V; Wojta J; Huber K
Int J Cardiol; 2013 Sep; 168(1):317-25. PubMed ID: 23041092
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
Friberg L; Rosenqvist M; Lip GY
Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
[TBL] [Abstract][Full Text] [Related]
10. Von Willebrand factor and ADAMTS13 plasma in older patients with high CHA2DS2-VASc Score with and without atrial fibrillation.
Zhang F; Yang XC; Jia XW; Tang XH; Wang Z; Wang ZQ
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4907-4912. PubMed ID: 29164570
[TBL] [Abstract][Full Text] [Related]
11. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
Banerjee A; Fauchier L; Vourc'h P; Andres CR; Taillandier S; Halimi JM; Lip GY
J Am Coll Cardiol; 2013 May; 61(20):2079-87. PubMed ID: 23524209
[TBL] [Abstract][Full Text] [Related]
12. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure.
Freestone B; Gustafsson F; Chong AY; Corell P; Kistorp C; Hildebrandt P; Lip GY
Chest; 2008 May; 133(5):1203-8. PubMed ID: 18339785
[TBL] [Abstract][Full Text] [Related]
13. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation.
Lip GY; Pearce LA; Chin BS; Conway DS; Hart RG
Heart; 2005 Jun; 91(6):759-63. PubMed ID: 15894770
[TBL] [Abstract][Full Text] [Related]
14. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors.
Conway DS; Pearce LA; Chin BS; Hart RG; Lip GY
Circulation; 2002 Oct; 106(15):1962-7. PubMed ID: 12370220
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery.
Hernández-Romero D; Lahoz Á; Roldan V; Jover E; Romero-Aniorte AI; Martinez CM; Jara-Rubio R; Arribas JM; Garcia-Alberola A; Cánovas S; Valdés M; Marín F
Europace; 2016 Sep; 18(9):1328-34. PubMed ID: 26566941
[TBL] [Abstract][Full Text] [Related]
16. Left atrial blood stasis and Von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation.
Ammash N; Konik EA; McBane RD; Chen D; Tange JI; Grill DE; Herges RM; McLeod TG; Friedman PA; Wysokinski WE
Arterioscler Thromb Vasc Biol; 2011 Nov; 31(11):2760-6. PubMed ID: 21852562
[TBL] [Abstract][Full Text] [Related]
17. Differences among clinical classification schemes for predicting stroke in atrial fibrillation: implications for therapy in daily practice.
Laguna P; Martín A; Del Arco C; Millán I; Gargantilla P;
Acad Emerg Med; 2005 Sep; 12(9):828-34. PubMed ID: 16141016
[TBL] [Abstract][Full Text] [Related]
18. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort.
Lip GY; Frison L; Halperin JL; Lane DA
Stroke; 2010 Dec; 41(12):2731-8. PubMed ID: 20966417
[TBL] [Abstract][Full Text] [Related]
19. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
Baruch L; Gage BF; Horrow J; Juul-Möller S; Labovitz A; Persson M; Zabalgoitia M
Stroke; 2007 Sep; 38(9):2459-63. PubMed ID: 17673721
[TBL] [Abstract][Full Text] [Related]
20. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels.
Freestone B; Chong AY; Nuttall S; Lip GY
Thromb Res; 2008; 122(1):85-90. PubMed ID: 17996280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
